BECTON

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device

Retrieved on: 
Thursday, December 7, 2023
Hypertension, Health equity, NYSE, BDX, Patient, FDA, Hematocrit, Health, Blood, Diagnosis, Partnership, Life, Pharmacy, Medical device, Pharmaceutical industry, Babson

FRANKLIN LAKES, N.J., Dec. 7, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.

Key Points: 
  • It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies.
  • The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing.
  • BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.
  • We believe the BD MiniDraw™ Collection System is potentially a game-changing innovation that combines convenience and better patient experience with lab-quality results."

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Retrieved on: 
Thursday, November 30, 2023
PICC, NYSE, BDX, Nursing, Patient, Central venous catheter, System, Workflow, Standard of care, Medical imaging

FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

Key Points: 
  • FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.
  • The SiteRite™ 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides industry-leading catheter placement tools and technologies to support clinicians during the vascular access device insertion process.
  • Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow.
  • As a global leader in vascular access solutions, BD is committed to advancing the standard of care for patients and health care providers.

BD Names Dr. Ronald Silverman as Chief Medical Officer

Retrieved on: 
Tuesday, November 21, 2023
Harvard University, Medicine, NYSE, Safety, BDX, Johns Hopkins, Biological engineering, Patient, Medical Affairs Bureau, FACS, Plastic surgery, University, Massachusetts General Hospital, Publication, Dentistry, MD, Engineering

FRANKLIN LAKES, N.J., Nov. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.

Key Points: 
  • FRANKLIN LAKES, N.J., Nov. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.
  • Dr. Silverman will report to Beth McCombs, executive vice president and chief technology officer for BD, and serve as a member of the BD Executive Leadership Team.
  • Dr. Silverman replaces Dr. William Sigmund, who has been chief medical officer for BD since January 2018 and announced his intent to retire from the company in June 2023.
  • Dr. Silverman joins BD from 3M Health Care, where he most recently served as senior vice president and chief medical officer since 2021.

BD to Present at the 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 14, 2023
NYSE, Conference, BDX, Rare-earth element, Computer data storage

FRANKLIN LAKES, N.J., Nov. 14, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 8:20 am Eastern Time.

Key Points: 
  • FRANKLIN LAKES, N.J., Nov. 14, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 8:20 am Eastern Time.
  • The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com .
  • A replay of the event will be available on the same webpage following its conclusion.

3D Cell Culture Market to grow by USD 1.28 billion from 2021 to 2026, cancer and stem cell research segment of the market growth - Technavio

Retrieved on: 
Tuesday, November 14, 2023
Thermo Fisher Scientific, Prevalence, ROW, Investment, Cancer, Regenerative medicine, Research, USD, Infection, World Games, Geography, Drug discovery, Tissue engineering, Growth, 3D, FREE, Corning Inc., Cell culture, 3D printing, Video game

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- The 3D cell culture market size is expected to grow by USD 1.28 billion from 2021 to 2026.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire/ -- The 3D cell culture market size is expected to grow by USD 1.28 billion from 2021 to 2026.
  • The 3D cell culture market share growth by cancer and stem cell research segment will be significant during the forecast period.
  • Read FREE PDF Sample Report
    3D Biotek LLC - The company offers 3D Cell Culture products such as 3D cell culture devices.
  • Growth of the 3D cell culture market in North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of 3D cell culture market vendors.

Life Science Equipment Market to Achieve $92.21 Billion Valuation by 2030, Driven by Advancements in Genomics and Proteomics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 7, 2023
Genetics, Science, Health, Other Science, Shimadzu, Food safety, Sartorius AG, Biotechnology, Prevalence, Research, ChromeOS, PerkinElmer, Bruker, Growth, Genomics, Danaher Corporation, Dickinson, SE, Agilent Technologies, Proteomics, Waters Corporation, Automation, Fine chemical

The "Life Science Equipment Market by Technology, End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Life Science Equipment Market by Technology, End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global life science equipment market is on a growth trajectory and is expected to reach a valuation of $92.21 billion by 2030, with a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030.
  • Pharmaceutical and Biotechnology Dominance: Among end users, the pharmaceutical and biotechnology industry segment is estimated to account for the largest share of the life science equipment market in 2023.
  • Regional Insights: In 2023, North America is anticipated to hold the largest share of the life science equipment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

US Anesthesia Drugs and Devices Market Set to Reach $6.83 Billion in 2023, Driven by Growing Healthcare Expenditure - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Pharmaceutical, Health, Medical Devices, Patient, Headache, Ageing, Anesthesiology, Pain, KKR, Vomiting, Abdominal ultrasonography, Somnolence, Prevalence, AstraZeneca, Conditional sentence, Lidocaine, Anesthetic, Shivering, MAC, Envision Healthcare, Nausea, 3M, Abbott Laboratories, General Electric Company, SunMed BRT station, Growth, Fungal infection, TeamHealth, COVID-19, Inhalation, Risk, AbbVie, Device, Benzocaine, Consciousness, Becton, Dickinson and Company headquarters, Blackstone, Braun, Baxter International, Ventilation, Central nervous system, ICU Medical, ICU, Pharmaceutical industry, Dentistry, Bupivacaine, Prilocaine, Anesthesia, Ropivacaine

The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.

Key Points: 
  • The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.
  • Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region.
  • In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia.
  • The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment.

Asia Cervical Cancer Screening Industry Research 2023-2028: Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunities, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Health, Oncology, Cervical cancer, Cardinal Health, AstraZeneca, Incidence, HPV, Mortality, Acetic acid, Cardinal, Roche, Quest Diagnostics, Visual inspection, Siemens, Woman, Diagnosis, VIA, Birth control, Vaccine, Growth

The "Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • With advanced technologies and increased emphasis on women's health, the Asia Pacific is experiencing positive trends in cervical cancer screening, leading to improved outcomes and lives saved.
  • Pap smear testing, also known as cervical cytology, is widely utilized for the early detection of cervical cancer and precancerous abnormalities.
  • These companies are at the forefront of developing and providing advanced solutions for cervical cancer screening and diagnosis.